Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that ...

Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock ...

Amgen stock trades in weekend trading at Lang & Schwarz at EUR 383.13 at 5:37 p.m. CEST on October 18, 2026. The quote page ...

Sept 22 () - Amgen said on Tuesday its experimental drug to treat an ‌autoimmune disease that attacks the body's ‌moisture-producing glands met the main goal of reducing disease ​activity in a ...

Amgen (AMGN) closed at $434.03 in the latest trading session, marking a +1.86% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.33%. Meanwhile, the Dow ...

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

Amgen (AMGN) closed at $414.87 in the latest trading session, marking a +1.82% move from the prior day. This move outpaced the S&P 500's daily gain of 0.6%. Elsewhere, the Dow saw an upswing of 0.83%, ...

Amgen joins a wave of biopharma giants announcing sporty sponsorships in recent weeks. (Los Angeles Sports & Entertainment Commission) Amgen is getting the ball rolling on a far-reaching new ...

Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.

Major market indexes such as the S&P 500 declined in the first few months of the year, but have since rebounded significantly. In contrast, biotech giant Amgen (AMGN +2.11%) started the year strong, ...

Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.

Amgen stock is at EUR 386.78 pre-market, according to Lang & Schwarz. The quote was recorded at 8:04 a.m. CEST on October 16, ...